PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status.

Abstract Cytology combined with HPV genotyping detection can more effectively estimate the morbidity risks of CIN2+ and CIN3+ . Both high prevalence rates and high risks associated with CIN2+ and CIN3+ of HPV31, HPV33, HPV52 and HPV58 are observed. NILM and ASC-US status combined with these subtypes mentioned above are advised to be conducted by colposcopy.
PMID
Related Publications

Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.

Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.

High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Authors

Mayor MeshTerms
Keywords

Cervical intraepithelial neoplasia

Human papillomavirus

Liquid based cytology

Matrix-assisted laser desorption/ionization time-of-flight

Journal Title zhonghua zhong liu za zhi [chinese journal of oncology]
Publication Year Start




PMID- 29575846
OWN - NLM
STAT- MEDLINE
DCOM- 20180406
LR  - 20180406
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 40
IP  - 3
DP  - 2018 Mar 23
TI  - [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined
      with abnormal cytology status].
PG  - 232-238
LID - 10.3760/cma.j.issn.0253-3766.2018.03.015 [doi]
AB  - Objective: To determine the morbidity of cervical intraepithelial neoplasia 2+
      (CIN2+ ) and CIN3+ of different human papillomavirus(HPV) subtype infection
      combined with different cytology status. Methods: The Shenzhen Cervical Cancer
      Screening Trial & (SHENCCAST&) are population-based cross-sectional cervical
      cancer screening studis conducted in Shenzhen and surrounding area from 2008 to
      2010. A total of 12 097 women who aged 25-59 years were included in the analysis.
      All of these women were detected by liquid-based cytology test and several
      high-risk HPV-DNA tests. The ones with HPV positive or atypical squamous cells of
      undetermined sign (ASC-US) were sequentially conducted by cervical biopsy
      vaginoscopy. Finally, 10 805 samples with complete data of hybrid capture 2(HC2),
      the polymerase chain reaction-based matrix-assisted laser desorption/ionization
      time-of-flight assay (MALDI-TOF), HPV genotyping detection, cytology and
      pathology results were analyzed. Results: The top 6 infection rates of HR-HPV in 
      CIN2+ and CIN3+ were HPV16, HPV52, HPV58, HPV33, HPV31, HPV18. The highest
      constituent ratio of cytology in CIN2+ and CIN3+ was high grade squamous
      intraepithelial lesion(HSIL). The morbidities of CIN2+ of patients infected with 
      HPV16, HPV31, HPV58, HPV33, HPV18, HPV52 were 41.3%, 31.5%, 30.6%, 28.7%, 28.2%, 
      17.7%, respectively, while the morbidities of CIN3+ of those were 33.5%, 20.5%,
      19.4%, 15.7%, 19.2%, 8.3%, respectively.The morbidities of CIN2+ in negative
      intraepithelial lesion or malignancy (NILM), ASC-US, low grade squamous
      intraepithelial lesion (LSIL), atypical squamous cell cannot exclude high-grade
      squamous intraepithelial lesion (ASC-H), high grade squamous intraepithelial
      lesion (HSIL), atypical glandular cell (AGC) samples were 0.4%, 6.9%, 11.1%,
      36.4%, 82.0%, 16.7%, respectively, while the morbidities of CIN3+ of those were
      0.2%, 3.1%, 4.2%, 22.7%, 64.8%, 0.0%, respectively. The morbidities of CIN2+ in
      NILM combined with HPV16, HPV18, HPV31, HPV33 infection were 12.6%, 13.3%, 15.8% 
      and 11.5%, respectively, while the morbidities of CIN3+ of those were 10.3%,
      11.1%, 7.9% and 7.7%, respectively.The morbidities of CIN2+ and CIN3+ in ASC-US
      combining with hrHPV infection were high, and the top 6 subtypes associated with 
      high risk of CIN2+ were HPV31 (35.7%), HPV33 (26.9%), HPV16 (26.5%), HPV58
      (22.4%), HPV52 (18.6%), HPV68 (15.4%), while those associated with high risk of
      CIN3+ were HPV16 (20.4%), HPV31 (14.3%), HPV33 (11.5%), HPV58 (8.6%), HPV68
      (7.7%), HPV52 (5.8%). Conclusions: Cytology combined with HPV genotyping
      detection can more effectively estimate the morbidity risks of CIN2+ and CIN3+ . 
      Both high prevalence rates and high risks associated with CIN2+ and CIN3+ of
      HPV31, HPV33, HPV52 and HPV58 are observed. NILM and ASC-US status combined with 
      these subtypes mentioned above are advised to be conducted by colposcopy.
FAU - Luo, H X
AU  - Luo HX
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China (Currently address: Department of Obstetrics and Gynecology, Peking
      University People' Hospital, Beijing 100044, China).
FAU - Du, H
AU  - Du H
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China.
FAU - Liu, Z H
AU  - Liu ZH
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China.
FAU - Zhang, L J
AU  - Zhang LJ
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China.
FAU - Wang, C
AU  - Wang C
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China.
FAU - Wu, R F
AU  - Wu RF
AD  - Department of Obstetrics and Gynecology, Shenzhen Key Laboratory of Gynecological
      Diagnostic Technology Research, Peking University Shenzhen Hospital, Shenzhen
      518036, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
SB  - IM
MH  - Adult
MH  - Atypical Squamous Cells of the Cervix
MH  - Cervical Intraepithelial Neoplasia/*pathology/*virology
MH  - Colposcopy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Genotype
MH  - Human Papillomavirus DNA Tests
MH  - Human papillomavirus 16/isolation & purification
MH  - Humans
MH  - Middle Aged
MH  - Papillomaviridae/genetics/*isolation & purification
MH  - Papillomavirus Infections/virology
MH  - Pregnancy
MH  - Risk
MH  - Uterine Cervical Neoplasms/*pathology/*virology
OTO - NOTNLM
OT  - Cervical intraepithelial neoplasia
OT  - Human papillomavirus
OT  - Liquid based cytology
OT  - Matrix-assisted laser desorption/ionization time-of-flight
EDAT- 2018/03/27 06:00
MHDA- 2018/04/07 06:00
CRDT- 2018/03/27 06:00
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2018 Mar 23;40(3):232-238.